IL6 and chronic kidney disease: Experiments in animal models showed IL-6 specific inhibitor, Fc-gp130 attenuated renal fibrosis and immune cells infiltration.259 The reducing cardiovascular event rates and renal progression effects of canakinumab, a human monoclonal antibody neutralizing IL-1β, were evaluated on CKD patients with stable post-myocardial infarction and high-sensitivity C-reactive protein ≥2 mg/L.